Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial
1. 系统已在2025-12-11 12:21:02对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/s1470-2045(25)00523-6
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S1470204525005236
其他信息:
出版社: Elsevier BV
作者: Huiping Li; Jieqiong Liu; Quchang Ouyang; Shusen Wang; Yaxin Liu; Yuee Teng; Xiaojia Wang; Jing Cheng; Zhongsheng Tong; Tao Sun; Min Yan; Xin Zhou; Fanfan Li; Jianyun Nie; Zhi-Ming Shao; Changsheng Ye; Yongsheng Wang; Xiaohong Wu; Zhihua Li; Yudong Wu; Huihua Xiong; Hui Li; Lu Gan; Zhaofeng Niu; Juliang Zhang; Qingyuan Zhang; Yueyin Pan; Xinhong Wu; Yi Zhang; Weimin Xie; Yu Xiao; Jinnan Gao; Huadong Zhao; Yongmei Yin; Zhiying Qian; Sanyuan Sun; Hongwei Zhang; Kun Wang; Jinsong Lu; Yong Li; Xinshuai Wang; Xinfeng Yang; Yuting Wang; Quanren Wang; Erwei Song
